Bristol Myers Squibb and 2seventy bio announced that the U.S. FDA will not meet the December 16 deadline for potential approval of their blood cancer therapy, Abecma, for earlier lines of treatment. As a result, shares of Bristol Myers Squibb and 2seventy bio fell premarket.
Verizon's recent $20B acquisition of Frontier Communications offers growth opportunities but also increases risk, potentially impacting dividends and stock outlook.
Boeing's troubled Starliner spacecraft is set to return to Earth uncrewed on Friday evening after undocking from the International Space Station.
Qualcomm is exploring acquiring parts of Intel's design business to enhance its product portfolio.
Fed Governor Christopher Waller stated, 'Given the progress on reducing inflation and the moderation in the labor market, I think it's time to lower the federal funds rate at our next meeting.' His comments came after a weaker-than-expected nonfarm payrolls report on Friday, which reinforced the idea that hiring is slowing down.
Nvidia remains a dominant player in the AI chip market with impressive revenue growth, but faces recent stock decline, CEO share sales, and competition despite robust Q2 2025 earnings and long-term opportunities in data center GPUs and liquid cooling technology.
Stock markets remain volatile as investors await a crucial jobs report, with concerns about the U.S. economy and recession fears causing significant market swings.
The Dutch government is expanding export restrictions on ASML's advanced semiconductor equipment, requiring new licenses for two more DUV lithography tools, aligning with US sanctions against China.
Samsara Inc. (IOT) reported better-than-expected Q2 earnings, with revenue at $300.2 million and raised its FY25 guidance.
UiPath reported strong Q2 financial results with ARR growing 19% year-over-year, raised its fiscal 2025 revenue guidance, and approved a $500 million stock buyback program, but shares fell despite positive news.